TY - JOUR T1 - Commentary on “Novel Interaction of the Dopamine D2 Receptor and the Ca<sup>2+</sup> Binding Protein S100B: Role in D2 Receptor Function” JF - Molecular Pharmacology JO - Mol Pharmacol SP - 91 LP - 94 DO - 10.1124/molpharm.121.000284 VL - 100 IS - 2 AU - Hun-Joo Lee AU - Dayana Rodriguez-Contreras AU - Kim A. Neve Y1 - 2021/08/01 UR - http://molpharm.aspetjournals.org/content/100/2/91.abstract N2 - We previously proposed that the dopamine D2 receptor–interacting protein S100B binds to a putative S100B-binding motif at residues R233–L240 toward the N terminus of the third intracellular loop. We used in vitro pull-down assays with FLAG-tagged fragments of the rat dopamine D2 receptor third intracellular loop (D2-IC3) and in vitro-synthesized S100B to evaluate this hypothesis. Our results indicate that the putative S100B-binding motif is neither necessary nor sufficient for strong binding of S100B to D2-IC3. Instead, two residues at the junction of the fifth membrane-spanning domain and the cytoplasmic extension of that α-helical domain, K211-I212, are required for robust, calcium-sensitive binding of S100B. This is also the approximate location of previously identified determinants for the binding of arrestin and calmodulin. A D2 receptor mutation converting I212 to phenylalanine has been described in patients with a hyperkinetic movement disorder.SIGNIFICANCE STATEMENT S100B is a small calcium-binding protein that modulates signaling by the dopamine D2 receptor. New data suggest that the previous hypothesis about the involvement of an S100B-binding motif is incorrect, and that an important determinant of S100B binding includes a residue that is mutated in patients with a hyperkinetic movement disorder. ER -